Effect of oseltamivir on bleeding risk associated with warfarin therapy: a retrospective review.

Abstract:

BACKGROUND:Warfarin is a commonly used oral anticoagulant and its interaction with other drugs can result in serious thrombotic or bleeding events. Currently, there is no definitive evidence on the possibility of an interaction between warfarin and oseltamivir. OBJECTIVE:The objective of this study was to investigate whether a possible drug interaction between oseltamivir and warfarin exists. METHODS:A retrospective review of patients on anticoagulation therapy who took oseltamivir from 1 September 2009 to 28 February 2010 at Seoul National University Hospital, Seoul, Korea, was carried out. RESULTS:Among 15 patients who were tested for prothrombin time/international normalized ratio (PT/INR) [hereafter referred to as INR] within 10 days of starting oseltamivir therapy and had previously stable INR values, seven patients had an increase in INR levels after oseltamivir administration, and the other eight patients maintained stable INR levels. The mean ± SD INR value was 2.08 ± 0.46 prior to the administration of oseltamivir and 5.15 ± 2.00 after treatment with oseltamivir (measured a mean ± SD 5.7 ± 2.5 days after the first dose of oseltamivir) in the INR-increased group and, respectively, 2.03 ± 0.40 and 1.97 ± 0.54 (measured 6.4 ± 2.5 days after the first dose of oseltamivir) in the INR-unaffected group. The dosage and duration of oseltamivir treatment were similar whether the INR values increased or not. There were bleeding events such as blood-tinged sputum and bloody ascites in three patients in the INR-increased group. The INR level recovered within 5 days after discontinuation of warfarin in these three patients. The positivity rates for influenza A H1N1 were not different between the INR-increased group and the INR-unaffected group. CONCLUSION:This case series suggests the possibility of a potential interaction between warfarin and oseltamivir. Further well designed prospective studies and genetic evaluations are needed to determine the exact nature of the interaction between warfarin and oseltamivir.

journal_name

Clin Drug Investig

authors

Lee SH,Kang HR,Jung JW,Kwon JW,Hong KS,Yu KS,Cho SH

doi

10.2165/11595860-000000000-00000

subject

Has Abstract

pub_date

2012-02-01 00:00:00

pages

131-7

issue

2

eissn

1173-2563

issn

1179-1918

journal_volume

32

pub_type

杂志文章
  • Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions.

    abstract:BACKGROUND AND OBJECTIVE:Several systematic reviews and meta-analyses have been conducted including an analysis to investigate the difference between ethnic groups in the glucose-lowering efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors. This study assessed the factors related to the glucose-lowering efficacy and ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s40261-016-0478-8

    authors: Fujita K,Kaneko M,Narukawa M

    更新日期:2017-03-01 00:00:00

  • A Literature Review of Psychotropic Medications and Alcohol as Risk Factors for Falls in Community Dwelling Older Adults.

    abstract::Psychotropic medications and alcohol are potential risk factors for falls in older adults. However, there has been no appraisal of the literature on whether these medications, both singly and in combination with alcohol, are associated with falls in community dwelling older adults (those aged 60 years and older living...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.1007/s40261-018-0721-6

    authors: Laberge S,Crizzle AM

    更新日期:2019-02-01 00:00:00

  • Hospitalization for severe bacterial infections in children after exposure to NSAIDs: a prospective adverse drug reaction reporting study.

    abstract:BACKGROUND:NSAIDs are widely used to treat fever and pain in children, but their possible role in the progression of some bacterial infections is controversial. OBJECTIVE:This study was performed to analyse reported cases of severe bacterial infection associated with NSAID exposure in children admitted for this reason...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/11532890-000000000-00000

    authors: Leroy S,Marc E,Bavoux F,Tréluyer JM,Gendrel D,Bréart G,Pons G,Chalumeau M

    更新日期:2010-01-01 00:00:00

  • Severe INR elevation in a patient with choledocholithiasis receiving cefoperazone.

    abstract::Cefoperazone is a third-generation cefalosporin that contains the N-methyl- thio-tetrazole (NMTT) side chain, which inhibits vitamin K-dependent carboxylation. Administration of NMTT-containing cefalosporins can cause alterations in the hepatic glutathione redox state, resulting in a dose-related increase in oxidised ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200626080-00006

    authors: Alagozlu H,Cindoruk M,Unal S

    更新日期:2006-01-01 00:00:00

  • Massive thrombosis of brachiocephalic veins and superior vena cava syndrome in a patient with non-small cell lung cancer treated with the epidermal growth factor receptor inhibitor erlotinib.

    abstract::The superior vena cava (SVC) syndrome occurs when obstruction of this vessel interrupts venous return of blood from the head, upper extremities and thorax to the right atrium. Most cases of SVC syndrome result from neoplasia, especially from lung cancer, but other non-cancer-associated causes may include fibrosis caus...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200727070-00007

    authors: Salmi R,Gaudenzi P,Di Todaro F,Morandi P,Nielsen I,Manfredini R

    更新日期:2007-01-01 00:00:00

  • Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.

    abstract:BACKGROUND AND OBJECTIVES:Mirabegron, a selective β3-adrenoceptor agonist for the treatment of overactive bladder (OAB), is eliminated by renal and metabolic routes. The potential influence of renal or hepatic impairment on the pharmacokinetics of mirabegron was evaluated. METHODS:Two separate open-label, single-dose,...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-012-0031-3

    authors: Dickinson J,Lewand M,Sawamoto T,Krauwinkel W,Schaddelee M,Keirns J,Kerbusch V,Moy S,Meijer J,Kowalski D,Morton R,Lasseter K,Riff D,Kupčová V,van Gelderen M

    更新日期:2013-01-01 00:00:00

  • Efficacy and Safety of the Platelet-Activating Factor Receptor Antagonist BN 52021 (Ginkgolide B) in Patients with Severe Sepsis : A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial.

    abstract:OBJECTIVE:To evaluate the efficacy and safety of the natural platelet-activating factor receptor antagonist, BN 52021 (ginkgolide B) in the treatment of patients with severe sepsis related to Gram-negative and mixed bacterial infection. DESIGN AND SETTING:Prospective, randomised, double-blind, placebo-controlled, mult...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200424030-00002

    authors: Albrecht DM,van Ackern K,Bender HJ,Hof H,Kox W,Victor N,Funk P,Kieser M,Köhler S,Krausch D,Marzi I,Menges T,Schmidt H

    更新日期:2004-01-01 00:00:00

  • Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.

    abstract::Early initiation of rational and effective combination therapy consisting of antihypertensive drugs with two different and complementary mechanisms of actions is increasingly becoming accepted in clinical practice and by guidelines as a first-line approach to control blood pressure (BP) and prevent cardiovascular outc...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.2165/11538440-000000000-00000

    authors: da Silva PM

    更新日期:2010-01-01 00:00:00

  • Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting.

    abstract:BACKGROUND AND OBJECTIVES:Statin-induced changes in high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) are unrelated. Many patients initiated on statins experience a paradoxical decrease in HDL-C. The aim of this study was to evaluate the association between a decrease in HDL-C...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-015-0372-9

    authors: Hasvold P,Thuresson M,Sundström J,Hammar N,Kjeldsen SE,Johansson G,Holme I,Bodegård J

    更新日期:2016-03-01 00:00:00

  • Concomitant Use of Direct Oral Anticoagulants and Antiepileptic Drugs: A Prospective Cohort Study in Patients with Atrial Fibrillation.

    abstract:BACKGROUND:European guidelines do not recommend the use of carbamazepine, levetiracetam, phenobarbital, phenytoin, topiramate and valproic acid in patients taking direct oral anticoagulants (DOACs). Little is known regarding the clinical relevance of the interaction between DOACs and antiepileptic drugs. OBJECTIVES:To...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-020-00982-8

    authors: Giustozzi M,Mazzetti M,Paciaroni M,Agnelli G,Becattini C,Vedovati MC

    更新日期:2021-01-01 00:00:00

  • A novel once-daily fixed-dose combination of memantine extended release and donepezil for the treatment of moderate to severe Alzheimer's disease: two phase I studies in healthy volunteers.

    abstract:BACKGROUND:Combining two standard-of-care medications for Alzheimer's disease (AD) into a single once-daily dosage unit may improve treatment adherence, facilitate drug administration, and reduce caregiver burden. A new fixed-dose combination (FDC) capsule containing 28 mg memantine extended release (ER) and 10 mg done...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40261-015-0296-4

    authors: Boinpally R,Chen L,Zukin SR,McClure N,Hofbauer RK,Periclou A

    更新日期:2015-07-01 00:00:00

  • Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.

    abstract:BACKGROUND AND OBJECTIVES:Lenvatinib is an oral, multitargeted tyrosine kinase inhibitor under clinical investigation in solid tumours. This study evaluated the influence of P-glycoprotein (P-gp) inhibition (single-dose rifampicin) and simultaneous cytochrome P450 3A4 (CYP3A4)/P-gp induction (multiple-dose rifampicin) ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-014-0217-y

    authors: Shumaker RC,Aluri J,Fan J,Martinez G,Thompson GA,Ren M

    更新日期:2014-09-01 00:00:00

  • Pharmacoeconomic impact of adverse events of long-term opioid treatment for the management of persistent pain.

    abstract::Opioids are the most powerful analgesic drugs currently available and consequently form an essential part of the treatment options for malignant and non-malignant chronic pain. However, the benefits of these medications can be offset by gastrointestinal adverse events such as nausea, vomiting and constipation, as well...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.1007/BF03256935

    authors: Annemans L

    更新日期:2011-01-01 00:00:00

  • Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland.

    abstract:BACKGROUND:Overactive bladder is a prevalent condition worldwide that is associated with a considerable burden, both on the patient and on society. OBJECTIVE:Our objective was to assess the economic value of fesoterodine compared with tolterodine extended release (ER) for the treatment of overactive bladder (OAB) with...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.1007/s40261-014-0178-1

    authors: Angulo JC,Valpas A,Rejas J,Linden K,Kvasz M,Snedecor SJ

    更新日期:2014-05-01 00:00:00

  • Combination therapy with milrinone and esmolol for heart protection in patients with severe sepsis: a prospective, randomized trial.

    abstract:BACKGROUND AND OBJECTIVE:As a β-adrenoceptor antagonist (β-blocker), esmolol can reduce cardiac output and the phosphodiesterase III inhibitor milrinone has been shown to improve heart contractility in patients with septic shock. This study was performed to assess the effects of esmolol combined with milrinone in patie...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40261-015-0325-3

    authors: Wang Z,Wu Q,Nie X,Guo J,Yang C

    更新日期:2015-11-01 00:00:00

  • Pantoprazole: a proton pump inhibitor.

    abstract::Pantoprazole is a proton pump inhibitor (PPI) that binds irreversibly and specifically to the proton pump, thereby reducing gastric acid secretion. Pantoprazole has a relatively long duration of action compared with other PPIs, and a lower propensity to become activated in slightly acidic body compartments. To date, n...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.2165/1153121-S0-000000000-00000

    authors: Moreira Dias L

    更新日期:2009-01-01 00:00:00

  • Ivabradine in Patients with Stable Coronary Artery Disease: A Rationale for Use in Addition to and Beyond Percutaneous Coronary Intervention.

    abstract::Heart rate is an established prognostic marker for longevity and is an important contributor in the pathophysiology of various cardiovascular diseases, including ischemic heart disease and heart failure. Most ischemic episodes are triggered by an increase in heart rate, which causes an imbalance between myocardial oxy...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.1007/s40261-016-0472-1

    authors: Godino C,Colombo A,Margonato A

    更新日期:2017-02-01 00:00:00

  • Drug interactions with levothyroxine therapy in patients with hypothyroidism: observational study in general practice.

    abstract:BACKGROUND AND OBJECTIVES:Several drugs may interact with levothyroxine and reduce its bioavailability. The aim of this study was to analyse the Italian general practice patients with hypothyroidism from 2002-2011, in terms of variation of thyroid-stimulating hormone (TSH) levels, number of levothyroxine prescriptions ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-015-0271-0

    authors: Trifirò G,Parrino F,Sultana J,Giorgianni F,Ferrajolo C,Bianchini E,Medea G,Benvenga S,Cricelli I,Cricelli C,Lapi F

    更新日期:2015-03-01 00:00:00

  • Efficacy, safety and pharmacokinetics of indacaterol in Caucasian and Japanese patients with chronic obstructive pulmonary disease: a comparison of data from two randomized, placebo-controlled studies.

    abstract:BACKGROUND:Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β2-adrenoceptor agonist that has been approved in the EU for the treatment of chronic obstructive pulmonary disease (COPD). Ethnic differences may influence the pharmacokinetics and pharmacodynamics of a drug, and it is therefore important to com...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.2165/11586520-000000000-00000

    authors: Hosoe M,Woessner R,Matsushima S,Lawrence D,Kramer B

    更新日期:2011-01-01 00:00:00

  • US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection.

    abstract::Elbasvir/grazoprevir demonstrated high sustained virologic response rates 12 weeks after the end of treatment (SVR12) across five clinical trials in subjects infected with chronic hepatitis C virus (HCV) genotype 1, including those with advanced chronic kidney disease (CKD), and GT4. Despite favorable results overall,...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-017-0492-5

    authors: Boyd SD,Tracy L,Komatsu TE,Harrington PR,Viswanathan P,Murray J,Sherwat A

    更新日期:2017-04-01 00:00:00

  • Effect of hyaluronidase on the pharmacokinetics of free and total platinum species after intra-arterial Cisplatin in refractory patients with colorectal liver metastases.

    abstract::A pharmacokinetic study was carried out in patients with unresectable colorectal liver metastases who had primarily been included in a phase II trial of intra-arterial cisplatin (DDP) plus intravenous fluorouracil. Ten patients of those accrued for the clinical study underwent the pharmacokinetic investigation upon li...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-199612020-00005

    authors: Civalleri D,Esposito M,De Cain F,Balletto N,Mondini G,Gogioso L,Viale M,Vannozzi MO

    更新日期:1996-08-01 00:00:00

  • Effectiveness and Safety of Amlodipine in Newly Diagnosed Hypertensive Patients and in Previously Diagnosed Hypertensive Patients not Controlled with their Usual Treatment (NOTA Study).

    abstract:OBJECTIVE:To evaluate the effectiveness and safety of amlodipine in two cohorts of hypertensive patients, one newly diagnosed and the other previously diagnosed but not controlled with drug therapy, and to assess the risk factors for the entire sample at the outset of the study. PATIENTS AND DESIGN:We designed a postm...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200323120-00001

    authors: Valcárcel Y,Jiménez R,Arístegui R,Gil A,Nota Study Group.

    更新日期:2003-01-01 00:00:00

  • Effects of a Novel Aldose Reductase Inhibitor, Fidarestat (SNK-860), on Vibration Perception Threshold and Subjective Symptoms in Patients with Diabetic Polyneuropathy : An Open-Label Pilot Study.

    abstract:OBJECTIVE:To evaluate the effects of fidarestat (SNK-860) on vibration perception threshold, as measured by C64 quantitative tuning fork (64Hz) analysis, as well as its effects on subjective symptoms in patients with diabetic polyneuro-pathy. DESIGN AND SETTING:Open-label, prospective study conducted at 12 hospitals i...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200424110-00006

    authors: Hotta N,Yasuda K,Sumita Y,Sano T,Kakuta H,Nagashima M,Hayashi Y,Yamamoto M,Wakao T,Okuyama M,Kobayashi M,Mori K

    更新日期:2004-01-01 00:00:00

  • Proton pump inhibitors in acute treatment of reflux oesophagitis : a cost-effectiveness analysis.

    abstract:BACKGROUND AND AIM:Gastro-oesophageal reflux disease is a common medical problem that places a significant financial burden on outpatient pharmaceutical expenditure. A substantial proportion of this expenditure can be attributed to the use of proton pump inhibitors (PPIs). The aim of this analysis was to evaluate the c...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200525050-00005

    authors: Lucioni C,Mazzi S,Rossi C

    更新日期:2005-01-01 00:00:00

  • Immediate neurological recovery following perispinal etanercept years after brain injury.

    abstract::Positron emission tomographic brain imaging and pathological examination have revealed that a chronic, intracerebral neuroinflammatory response lasting for years after a single brain injury may occur in humans. Evidence suggests the immune signaling molecule, tumor necrosis factor (TNF), is centrally involved in this ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-014-0186-1

    authors: Tobinick E,Rodriguez-Romanacce H,Levine A,Ignatowski TA,Spengler RN

    更新日期:2014-05-01 00:00:00

  • The Association between Polypharmacy and Hip Fracture in Osteoporotic Women: A Nested Case-Control Study in South Korea.

    abstract:BACKGROUND AND OBJECTIVE:Polypharmacy, regarded as an indicator of potentially inappropriate medications (PIMs), may lead to a higher risk of serious health consequences in elderly patients with osteoporosis. Thus, this study aimed to analyze the association between polypharmacy and hip fracture in patients with osteop...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-018-0716-3

    authors: Park HY,Kim S,Sohn HS,Kwon JW

    更新日期:2019-01-01 00:00:00

  • Efficacy of L-carnitine in reducing hyperammonaemia and improving neuropsychological test performance in patients with hepatic cirrhosis : results of a randomised trial.

    abstract:OBJECTIVES:To determine the efficacy of L-carnitine in reducing hyperammonaemia and improving neuropsychological performance in patients with hepatic cirrhosis and subclinical hepatic encephalopathy (SHE). DESIGN:Randomised, parallel group, controlled trial. PATIENTS AND METHODS:The study enrolled 31 patients with he...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200222001-00002

    authors: Cecere A,Ciaramella F,Tancredi L,Romano C,Gattoni A

    更新日期:2002-11-01 00:00:00

  • Bemiparin versus unfractionated heparin as bridging therapy in the perioperative management of patients on vitamin K antagonists: the BERTA study.

    abstract:BACKGROUND AND OBJECTIVE:The management of patients on vitamin K antagonist therapy who require an invasive procedure is problematic. A randomised, controlled, double-blind clinical trial was designed to compare the efficacy and safety of bemiparin, a low molecular weight heparin (LMWH), with unfractionated heparin (UF...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40261-013-0141-6

    authors: Santamaría A,Ugarriza A,Muñoz C,De Diego I,López-Chulia F,Benet C,Martínez-González J,Gómez N,Pina E,Ortín X,Marco P,Roncalés FJ,Fontcuberta J

    更新日期:2013-12-01 00:00:00

  • Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational study.

    abstract:BACKGROUND AND OBJECTIVES:Cancer pain affects patients at all stages of the disease and there are clear guidelines for its management. Morphine is considered the first-choice strong opioid in the treatment of moderate-to-severe pain; however, numerous studies have shown that oxycodone controlled-release (CR) has a simi...

    journal_title:Clinical drug investigation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.2165/00044011-200828070-00001

    authors: Silvestri B,Bandieri E,Del Prete S,Ianniello GP,Micheletto G,Dambrosio M,Sabbatini G,Endrizzi L,Marra A,Aitini E,Calorio A,Garetto F,Nastasi G,Piantedosi F,Sidoti V,Spanu P

    更新日期:2008-01-01 00:00:00

  • Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.

    abstract:BACKGROUND:Patients with schizophrenia or related disorders often switch antipsychotic therapy, most commonly due to lack of efficacy and side effects. The differences in anticipated efficacy and tolerability among atypical antipsychotics may drive switching behaviours. Switching to long-acting antipsychotics may impro...

    journal_title:Clinical drug investigation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.2165/11599080-000000000-00000

    authors: Rosa F,Schreiner A,Thomas P,Sherif T

    更新日期:2012-04-01 00:00:00